A newly released 2021 email shows that the acting head of the Food and Drug Administration urged Dr. Anthony Fauci and Dr. Francis Collins to investigate reports of difficult-to-characterize health problems following COVID-19 vaccination, warning that existing surveillance systems might not adequately capture them.
The May 27, 2021, correspondence from then-acting FDA Commissioner Janet Woodcock was released by Republican Wisconsin Sen. Ron Johnson after being obtained from Fauci’s government email account.
Woodcock told Fauci and Collins, then the respective leaders of the National Institute of Allergy and Infectious Diseases and National Institutes of Health, that she was hearing reports of adverse health experiences, including from healthcare professionals.
“The symptoms do not fit together into a distinctive syndrome and most are not easily quantifiable or evaluated with standard laboratory testing,” Woodcock wrote.
She acknowledged that a mass vaccination campaign would inevitably generate unrelated illnesses and psychological reactions, making causation difficult to determine. But she said the reports nevertheless deserved serious scientific examination.
“The peoples’ main complaint is that no one takes them seriously, no one knows how to treat them, and there is no effort to study this,” she wrote.
Woodcock proposed conducting research even if vaccine manufacturers were unwilling to support it.
“I doubt the industry would support, for obvious reasons,” she wrote. “But my experience is, that if you let a problem fester, then it will come back to bite you later and you are not prepared.”
Perhaps most notably, Woodcock questioned whether the government’s existing vaccine-monitoring tools were capable of identifying the kinds of problems being described.
She specifically referenced the Vaccine Adverse Event Reporting System, or VAERS, along with more sophisticated CDC and FDA monitoring systems.
“These problems are not the sort that a system like VAERS would be able to detect, or even a more sophisticated population-based active followup such as CDC has, or a medical record based system such as BEST,” Woodcock wrote.
VAERS is an early-warning surveillance system that accepts reports of health events occurring after vaccination. Such reports can identify signals requiring investigation, but they generally cannot establish by themselves that a vaccine caused a reported condition.
Fauci’s response indicates that Woodcock’s concerns received his attention.
“Janet asks what we think of this? We cannot ignore her,” Fauci wrote to Collins. “We should probably bring in CDC and see what Rochelle thinks.”
“Rochelle” apparently referred to then-CDC Director Rochelle Walensky.
Johnson’s office says the available records do not establish whether Walensky was subsequently brought into the discussion. It also remains unclear from the released correspondence whether NIH ultimately commissioned the particular kind of research Woodcock was proposing.
That distinction matters. The email demonstrates that Woodcock recommended further study and that Fauci said her concerns could not be ignored. By itself, it does not establish that Fauci or Collins deliberately blocked such research, nor does it prove that the reported medical problems were caused by COVID vaccines.
The correspondence nevertheless adds another piece to congressional investigations into how federal agencies handled potential vaccine safety signals during the massive 2021 vaccination campaign.
Johnson’s investigators previously released material involving former FDA Center for Biologics Evaluation and Research Director Peter Marks. According to an April 2026 Senate report, Marks was warned that FDA safety systems could lack sufficient sensitivity to identify certain statistically significant adverse events.
Marks expressed concern that an analysis could “create erroneous conflicts that feed in to anti-vaccination rhetoric,” according to the Senate report.
The newly released Woodcock email presents the issue from another direction. Rather than relying entirely on existing surveillance, the acting FDA commissioner was suggesting targeted scientific research capable of examining complaints that did not fit neatly into established diagnoses or laboratory measurements.
At the time, NIH controlled billions of dollars in biomedical research funding, while Fauci’s NIAID had a multibillion-dollar annual research budget.
Fauci, Collins, Marks and Woodcock did not immediately provide responses to requests for comment described in the report.


